Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Allergic Fungal Rhinosinusitis After Surgery
NCT06461949Phase 3Withdrawn
- Sponsor
- National Institute on Deafness and Other Communication Disorders
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in allergic fungal rhinosinusitis (AFRS) comparing Dupilumab with Placebo (2 arms). Primary endpoints: Endoscopic modified Lund-Kennedy score at 52 weeks and Incidence of oral corticosteroid utilization at 52 weeks. Planned start Jul 2024; status: withdrawn.
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on NCT06461949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461949.